Use of technetium-99m-MAG3 for renal scintigraphy after angiotensin-converting enzyme inhibition. 1991

M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
Department of Nuclear Medicine, S. Orsola-Malpighi Policlinic Hospital, Bologna, Italy.

Technetium-99m-mercaptoacetyltriglycine (99mTc-MAG3) was tested in 82 hypertensive patients submitted to renal scintigraphy 1 hr after oral premedication with 50 mg of Captopril. Baseline studies were obtained only for those patients showing abnormal findings in the provocative study. All patients underwent renal arteriography. Sensitivity and specificity for the detection of renal artery stenosis (RAS) greater than 50% were 89% and 91%, respectively. After Captopril administration, tracer parenchymal transit time increased significantly in ischemic kidneys (334 +/- 93 sec in baseline conditions versus 468 +/- 96 sec after Captopril, p less than 0.001) but not in kidneys with no RAS or RAS less than 50% (243 +/- 46 sec versus 271 +/- 95 sec, p = ns). False-positive responses were mostly bilateral and associated with a marked decrease in blood pressure. Technetium-99m-MAG3 is an effective compound for detecting RAS greater than or equal to 50% with Captopril renal scintigraphy. Performing the provocative test as a first step considerably reduced the number of scintigraphic studies required.

UI MeSH Term Description Entries
D008297 Male Males
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D012078 Renal Artery Obstruction Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR). Renal Artery Stenosis,Obstruction, Renal Artery,Obstructions, Renal Artery,Renal Artery Obstructions,Renal Artery Stenoses,Stenoses, Renal Artery,Stenosis, Renal Artery
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
August 2005, Clinical nuclear medicine,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
March 1993, Der Urologe. Ausg. A,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
March 1997, Kaku igaku. The Japanese journal of nuclear medicine,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
March 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
April 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
December 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
January 1984, Scandinavian journal of urology and nephrology. Supplementum,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
July 1984, Scandinavian journal of urology and nephrology,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
November 1981, Kidney international,
M Dondi, and N Monetti, and S Fanti, and F Marchetta, and C Corbelli, and P Zagni, and A De Fabritis, and F Losinno, and M Levorato, and A Zuccalá
January 1985, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!